| Recruiting | A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants NCT07060885 | ALK-Abelló A/S | Phase 3 |
| Completed | Study of BLU-808 in Allergic Rhinoconjunctivitis NCT06922448 | Blueprint Medicines Corporation | Phase 2 |
| Recruiting | Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber NCT06778213 | Wroclaw Medical University | Phase 4 |
| Completed | Dietary Supplement (Beta-Glucans) in Allergic Patients Undergoing Subcutaneous Immunotherapy. NCT06448585 | Gala Servicios Clinicos S.L. | Phase 4 |
| Not Yet Recruiting | Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen NCT05641272 | Inmunotek S.L. | Phase 2 / Phase 3 |
| Completed | Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Ast NCT05668390 | Stallergenes Greer | Phase 3 |
| Unknown | Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivit NCT05400811 | Inmunotek S.L. | Phase 3 |
| Completed | Effect of holoBLG on Cat Allergic Patients NCT05455749 | Allergy Therapeutics | N/A |
| Completed | Andosan in Allergic and Asthma Patients NCT05192720 | University Hospital, Akershus | N/A |
| Terminated | Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis NCT04874714 | Inmunotek S.L. | Phase 3 |
| Completed | Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction NCT04502966 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Adolescent Mite Allergy Safety Evaluation NCT04541004 | ALK-Abelló A/S | Phase 3 |
| Completed | Demonstration of a Decongestant Effect of "Coldamaris Akut" Compared to Saline Nasal Spray. NCT04532762 | Marinomed Biotech AG | N/A |
| Completed | Demonstration of an Anti-allergic Effect in Subjects Treated With Callergin Nasal Spray in Comparison to Untre NCT04531358 | Marinomed Biotech AG | N/A |
| Completed | Probiotic Chewables in Allergic Rhinoconjunctivitis Patients NCT04898686 | University Hospital, Antwerp | N/A |
| Terminated | A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber NCT04176185 | ALK-Abelló A/S | Phase 3 |
| Completed | Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis NCT03887026 | Emergo Therapeutics, Inc. | Phase 2 |
| Completed | Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study NCT03682965 | Christopher Thompson, MD | Phase 2 |
| Completed | S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen NCT04912076 | Odense University Hospital | Phase 1 |
| Completed | Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients NCT03850626 | Leti Pharma GmbH | — |
| Completed | Efficacy and Safety of Lertal® as an add-on to Standard Therapy for Allergic Rhinoconjunctivitis in Pediatrics NCT03365648 | NTC srl | N/A |
| Completed | Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Allergic Rhinoconjunctiv NCT02881879 | Roxall Medicina España S.A | Phase 1 |
| Completed | Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy NCT02556801 | HAL Allergy | Phase 2 |
| Completed | A Dose-response Evaluation of the SQ Tree SLIT-tablet Using an Environmental Exposure Chamber NCT02481856 | ALK-Abelló A/S | Phase 2 |
| Completed | Study for Evaluating Life Quality in Patients With Rhinoconjunctivitis NCT02488447 | Roxall Medicina España S.A | — |
| Unknown | Nasal Mucus Proteome and Immunotherapy NCT02159404 | Medical University of Graz | — |
| Completed | The Impact of Grass SLIT Treatment on Birch Pollen Induced Allergic Rhinitis - a Pilot Evaluation NCT02394600 | Queen's University | Phase 4 |
| Completed | An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy NCT02069535 | ALK-Abelló A/S | Phase 2 |
| Terminated | Evaluation of the Utility of an EEC for Assessing Efficacy of SIT in Pivotal Clinical Trials NCT02297490 | Allergopharma GmbH & Co. KG | Phase 2 |
| Completed | MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009 NCT01852825 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP NCT01966224 | Immunomic Therapeutics, Inc. | Phase 1 |
| Completed | PURETHAL Birch RUSH Study NCT01918956 | HAL Allergy | Phase 4 |
| Completed | Quality of Life in Allergic Rhinoconjunctivitis Patients Treated With Dialyzable Leukocyte Extracts NCT02506998 | National Polytechnic Institute, Mexico | Phase 2 |
| Completed | A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) NCT01707069 | Immunomic Therapeutics, Inc. | Phase 1 |
| Completed | SUBLIVAC FIX Phleum Pratense DT/DRF NCT01682070 | HAL Allergy | Phase 2 |
| Completed | SUBLIVAC FIX Birch Dose Tolerability/Dose Range Finding NCT01639768 | HAL Allergy | Phase 2 |
| Completed | Dose-response Study With Subcutaneous Immunotherapy of an Standardized Dermatophagoides Pteronyssinus (DPT) Ex NCT01564017 | Roxall Medicina España S.A | Phase 2 |
| Completed | Efficacy and Safety of Intraseasonal Specific Immunotherapy With Depiquick® Birch NCT01902992 | Novartis | Phase 3 |
| Completed | A Survey of Adults and Children With Allergic Rhinoconjunctivitis (MK-7243-021) NCT01535118 | ALK-Abelló A/S | — |
| Completed | Vitamin D and Grass Pollen Specific Immunotherapy NCT01466465 | Charite University, Berlin, Germany | Phase 2 |
| Completed | Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense NCT01567306 | Roxall Medicina España S.A | Phase 2 |
| Completed | PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis NCT01438463 | HAL Allergy | Phase 2 |
| Completed | Avanz Phleum Pratense Maintenance Dose NCT01438827 | ALK-Abelló A/S | Phase 2 / Phase 3 |
| Completed | An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy NCT01454531 | ALK-Abelló A/S | Phase 2 / Phase 3 |
| Completed | Subcutaneous Immunotherapy in Patients Sensitized to Dermatophagoides Pteronyssinus (DPT) NCT01489020 | Roxall Medicina España S.A | Phase 1 |
| Completed | Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunct NCT01490411 | Allergopharma GmbH & Co. KG | Phase 2 |
| Completed | Application of Ectoine Containing Nasal Spray and Eye Drops in Patients With Allergic Rhinitis NCT02131051 | Bitop AG | — |
| Completed | Changes in Specific Immunoglobulin and Blood Basophil Activity During Subcutaneous Immunotherapy in Allergic R NCT01085526 | Aarhus University Hospital | N/A |
| Completed | PURETHAL Grasses Rush Study NCT01059266 | HAL Allergy | Phase 4 |
| Completed | Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjuncti NCT01081574 | Faes Farma, S.A. | Phase 1 / Phase 2 |
| Completed | Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense NCT01489033 | Roxall Medicina España S.A | Phase 1 |
| Completed | Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC) NCT00985296 | ORA, Inc. | — |
| Completed | Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX® NCT02437786 | ALK-Abelló A/S | Phase 4 |
| Completed | Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis Patients NCT00973453 | HAL Allergy | Phase 2 |
| Unknown | A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis NCT00812799 | Artu Biologicals | Phase 3 |
| Completed | A Pilot Study Evaluating the Signs and Symptoms of Seasonal Allergic Rhinoconjunctivitis Following Exposure in NCT00985075 | ORA, Inc. | — |
| Completed | Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects With Epicutanoeus Allergen Administ NCT00777374 | University of Zurich | Phase 2 |
| Completed | A Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine NCT01740284 | ALK-Abelló A/S | Phase 3 |
| Completed | Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children NCT00841256 | Allergopharma GmbH & Co. KG | Phase 3 |
| Completed | Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Parietaria Judaica NCT00916760 | Laboratorios Leti, S.L. | Phase 3 |
| Completed | Immunological and Histological Evaluation of Specific Immunotherapy With Recombinant Hypoallergenic Derivative NCT00841516 | Allergopharma GmbH & Co. KG | Phase 2 |
| Completed | Tolerability of Grazax in Patients With Hayfever in Real Life Settings NCT01433510 | ALK-Abelló A/S | Phase 4 |
| Completed | Long-term Efficacy and Safety Study With Oralgen Grass Pollen NCT00824447 | Artu Biologicals | Phase 2 / Phase 3 |
| Completed | Efficacy-safety Study of Sublingual Immunotherapy With Depigmented-polymerized Pollen Extracts to Treat Rhinoc NCT00550875 | Laboratorios Leti, S.L. | Phase 2 |
| Completed | Normal Values of Facial Thermography NCT00411606 | West Penn Allegheny Health System | — |
| Completed | Efficacy and Safety of Grass Pollen Sublingual Immunotherapy NCT00567346 | Artu Biologicals | Phase 2 / Phase 3 |